Hexarelin

Research-Grade

Hexarelin is a synthetic hexapeptide GHRP that, like GHRP-2 and GHRP-6, agonizes GHSR-1a to drive GH release. Its distinguishing feature is activity at CD36 scavenger receptors in cardiac tissue, which has produced reproducible cardioprotective effects in preclinical ischemia-reperfusion models — an effect not shared by other GHRPs. Like other non-selective GHRPs, Hexarelin elevates cortisol and prolactin at chronic doses. Desensitization is also reported: repeated Hexarelin administration produces diminishing GH responses over time, more than other GHRPs. It was studied in several phase-2 oncology and cardiac trials that did not advance to commercialization. Off-label use is limited; the desensitization issue discourages chronic protocols.